Literature DB >> 15478066

Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics.

Sally Blower1, Anna Wald, Hayley Gershengorn, Fei Wang, Larry Corey.   

Abstract

BACKGROUND: Classic modeling of sexually transmitted diseases has focused on modeling behavioral heterogeneity and designing epidemic control strategies targeted at behavioral core groups.
METHODS: We analyzed a new mathematical model of herpes simplex virus type 2 (HSV-2) epidemics that includes virological core groups (i.e., groups of individuals with high rates of viral reactivation) and suggest a new paradigm for epidemic control. We used our model, in conjunction with virological data, to determine the potential role of virological core groups in contributing to transmission and the effect that daily antiviral therapy (DAT) could have on reducing transmission if virological core groups were targeted.
RESULTS: We estimated that a virological core group (11% of infected individuals) can cause a disproportionately large percentage (44%) of new infections and that a median of only 6.4 person-years of DAT would be necessary to prevent 1 HSV-2 infection. We determined that relatively few individuals would need to receive DAT to substantially reduce the incidence of HSV-2 infection.
CONCLUSION: Identifying and targeting individuals in the virological core group could be an effective and practical public health strategy for reducing transmission. Treating individuals who are high-frequency viral shedders should be evaluated as a strategy for reducing HSV-2 transmission.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15478066     DOI: 10.1086/424850

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.

Authors:  Ramzi A Alsallaq; Joshua T Schiffer; Ira M Longini; Anna Wald; Lawrence Corey; Laith J Abu-Raddad
Journal:  Sex Transm Dis       Date:  2010-05       Impact factor: 2.830

2.  Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.

Authors:  Melissa M Herbst-Kralovetz; Richard B Pyles
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling.

Authors:  Catherine M Crespi; William G Cumberland; Anna Wald; Lawrence Corey; Sally Blower
Journal:  Sex Transm Infect       Date:  2007-05-02       Impact factor: 3.519

Review 4.  Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling.

Authors:  A S Magaret; C Johnston; A Wald
Journal:  Sex Transm Infect       Date:  2009-02-11       Impact factor: 3.519

5.  Rational choices for allocating antiretrovirals in Africa: treatment equity, epidemiological efficiency, and feasibility.

Authors:  David P Wilson; Sally M Blower
Journal:  PLoS Med       Date:  2006-03-28       Impact factor: 11.069

6.  Designing equitable antiretroviral allocation strategies in resource-constrained countries.

Authors:  David P Wilson; Sally M Blower
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

7.  Epidemiological impact of a genital herpes type 2 vaccine for young females.

Authors:  Yijun Lou; Redouane Qesmi; Qian Wang; Marc Steben; Jianhong Wu; Jane M Heffernan
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.